SCHEMBL391547

SCHEMBL391547

COC(=O)c1cc(OCc2ccccc2)cc(OCc2ccccc2)c1

nearest known ligand 0.71

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.71
KMT2A Q03164 3/20 0.71
LMNA P02545 1/20 0.70
HPGD P15428 1/20 0.70
MAOB P27338 3/20 0.59
NR4A2 P43354 2/20 0.58
SMN1; SMN2 Q16637 3/20 0.57
SMPD1 P17405 1/20 0.56
MRGPRX4 Q96LA9 2/20 0.55
NR4A1 P22736 1/20 0.54
NR4A3 Q92570 1/20 0.54
RAB9A P51151 3/20 0.54
NPC1 O15118 2/20 0.54
PTPN1 P18031 1/20 0.54
GCK P35557 1/20 0.53
MAPT P10636 2/20 0.52
TSHR P16473 1/20 0.52
PARP10 Q53GL7 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL183994 0.97 LMNA (0.70) MEN1KMT2ALMNAHPGDMAOB
SCHEMBL29788280 0.95 LMNA (0.65) MEN1KMT2ALMNAHPGDMAOB
SCHEMBL340311 0.95 LMNA (0.65) MEN1KMT2ALMNAHPGDMAOB
SCHEMBL90412 0.92 LMNA (0.69) MEN1KMT2ALMNAHPGDMAOB
SCHEMBL3129603 0.92 MEN1 (0.74) MEN1KMT2ALMNAHPGDMAOB
SCHEMBL29475634 0.92 LMNA (0.69) MEN1KMT2ALMNAHPGDMAOB
SCHEMBL9323928 0.92 LMNA (0.60) MEN1KMT2ALMNAHPGDMAOB
SCHEMBL2650902 0.92 LMNA (0.60) MEN1KMT2ALMNAHPGDMAOB
SCHEMBL7362723 0.91 HPGD (0.63) MEN1KMT2ALMNAHPGDMAOB
SCHEMBL2808656 0.90 LMNA (0.59) MEN1KMT2ALMNAHPGDMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9201001-B2 Visual detection of fluoride ions INDIAN INSTITUTE OF TECHNOLOGY MADRAS (IN) 2015-12-01 US disclosed
US-9201001-B2 Visual detection of fluoride ions INDIAN INSTITUTE OF TECHNOLOGY MADRAS (IN) 2015-12-01 US disclosed
US-20140357894-A1 VISUAL DETECTION OF FLUORIDE IONS EMPIRE TECHNOLOGY DEVELOPMENT LLC 2014-12-04 US disclosed
US-20140357894-A1 VISUAL DETECTION OF FLUORIDE IONS EMPIRE TECHNOLOGY DEVELOPMENT LLC 2014-12-04 US disclosed
US-8828735-B2 Visual detection of fluoride ions INDIAN INSTITUTE OF TECHNOLOGY MADRAS (IN) 2014-09-09 US disclosed
US-8828735-B2 Visual detection of fluoride ions INDIAN INSTITUTE OF TECHNOLOGY MADRAS (IN) 2014-09-09 US disclosed
EP-2049459-B1 NOVEL PROCESS FOR THE SYNTHESIS OF (E)-STILBENE DERIVATIVES WHICH MAKES IT POSSIBLE TO OBTAIN RESVERATROL AND PICEATANNOL CLARIANT SPECIALTY FINE CHEM F (FR) 2013-10-02 EP disclosed
EP-2202215-B1 Novel process for the synthesis of (E)-Stilbene derivatives which makes it possible to obtain resveratrol and piceatannol CLARIANT SPECIALTY FINE CHEM F (FR) 2013-10-02 EP disclosed
US-8101804-B2 Process for the synthesis of (E)-stilbene derivatives which makes it possible to obtain resveratrol and piceatannol CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) 2012-01-24 US disclosed
EP-2202215-A2 Novel process for the synthesis of (E)-Stilbene derivatives which makes it possible to obtain resveratrol and piceatannol Clariant Specialty Fine Chemicals (France) (FR) 2010-06-30 EP disclosed
US-6656971-B2 Non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilins; inhibiting their peptidyl-prolyl isomerase activity; treating variety of medical conditions GUILFORD PHARMACEUTICALS INC. 2003-12-02 US disclosed
EP-1360173-A2 TRISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIR USE GUILFORD PHARMACEUTICALS INC. (US) 2003-11-12 EP disclosed
US-20020165275-A1 Trisubstituted carbocyclic cyclophilin binding compounds and their use GUILFORD PHARMACEUTICALS INC. 2002-11-07 US disclosed
WO-2002059080-A2 TRISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIR USE GUILFORD PHARMACEUTICALS INC. (US) 2002-08-01 WO disclosed
US-5863947-A Phenylglycine derivatives useful for treating disorders of the central nervous system ELI LILLY AND COMPANY LIMITED (GB) 1999-01-26 US disclosed
EP-0807621-A1 Derivatives of phenylglycine and use thereof as pharmaceuticals LILLY INDUSTRIES LIMITED (GB) 1997-11-19 EP disclosed
US-5446189-A Diester intermediates for diacid enzyme inhibitor HOFFMANN-LA ROCHE INC. (US) 1995-08-29 US disclosed
US-5324747-A Treatment of inflammatory diseases HOFFMANN-LA ROCHE INC. (US) 1994-06-28 US disclosed
EP-0579066-A2 N-substituted anilines F. HOFFMANN-LA ROCHE AG (CH) 1994-01-19 EP disclosed
US-5041516-A Macromolecules CORNELL RESEARCH FOUNDATION, INC. (US) 1991-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140357894-A1 VISUAL DETECTION OF FLUORIDE IONS HNRNPL, HNRNPLL, ARAF MEN1 3189/4885KMT2A 1693/4885LMNA 1059/4885
US-20020165275-A1 Trisubstituted carbocyclic cyclophilin binding compounds and their use FKBP2, PPIG, FKBP8 MEN1 4867/4885KMT2A 4618/4885LMNA 4803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.